« Back
Home /
Ralimetinib dimesylate

Ralimetinib dimesylate

Item no.	HY-13241-10mg
Manufacturer	MedChem Express
CASRN	862507-23-1
Amount	10 mg
Quantity options	100 mg 10mM/1mL 10 mg 1 mg 50 mg 5 mg
Category	Oncology Neuroscience Neural Lineage Markers Neuroinflammation Metabolism Diabetes Glucose Homeostasis Molecular Targets for Neuroscience Targets for Rodent Neurosciences Inhibitors & Compound Libraries Small Molecules By Organ Lymphatic System Cancer Oligodendrocyte Markers
Type	Inhibitors
Clone	N/A
Specific against	other
Purity	99.91
Formula	C26H37FN6O6S2
Citations	bioRxiv. 2023 Feb 8. Cell Death Dis. 2021 Oct 23;12(11):994. Cell Rep. 2023 Mar 20;42(3):112275. EBioMedicine. 2015 Nov 19;2(12):1944-56. Harvard Medical School LINCS LIBRARY Mol Cell Biol. 2025 Feb 2:1-17. Mol Med Rep 2019 Jul;20(1):735-744. Nat Commun. 2021 Dec 3;12(1):6941. Sci Transl Med. 2018 Jul 18;10(450):eaaq1093. Cell Biol Int. 2019 Jul 19. Commun Biol. 2022 Dec 20;5(1):1391. Eur J Immunol. 2020 Sep;50(9):1350-1361. Glia. 2020 Jan;68(1):27-43. [1]Mader M, et al. Imidazolyl benzimidazoles and imidazo[4,5-b]pyridines as potent p38alpha MAP kinase inhibitors with excellent in vivo antiinflammatory properties. Bioorg Med Chem Lett, 2008, 18(1), 179-183. [2]Ishitsuka K, et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol, 2008, 141(5), 598-606. [3]Campbell RM, et al. Characterization of LY2228820 dimesylate, a potent and selective inhibitor of p38 MAPK with antitumor activity. Mol Cancer Ther. 2014 Feb;13(2):364-74.
Smiles	FC1=CC=C(C=C1)C2=C(NC(C(C)(C)C)=N2)C3=NC4=C(C=C3)N=C(N)N4CC(C)(C)C.OS(C)(=O)=O.OS(C)(=O)=O
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	LY2228820 dimesylate
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; Autophagy; p38 MAPK
Shipping Temperature	Room Temperature
Storage Conditions	4°C (Powder, sealed storage, away from moisture)
Molecular Weight	612.74
Product Description	Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC50s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.
Manufacturer - Research Area	Cancer; Inflammation/Immunology
Solubility	DMSO : 61 mg/mL (ultrasonic; warming)\|H2O : ≥ 33.33 mg/mL
Manufacturer - Pathway	Apoptosis; Autophagy; MAPK/ERK Pathway
Isoform	p38α; p38β
Clinical information	Phase 2

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-13241-10mg-safety-datasheet.pdf